Related Experiment Videos
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
M A Dimopoulos1, A Palumbo, M Attal
1Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece. mdimop@med.uoa.gr
Leukemia
|February 5, 2011
Summary
Lenalidomide and dexamethasone (Len/Dex) is an effective treatment for relapsed or refractory multiple myeloma (RRMM). Early use of Len/Dex offers better outcomes than later use, with dose adjustments for specific patient needs.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Relapsed or refractory multiple myeloma (RRMM) presents significant treatment challenges.
- Lenalidomide in combination with dexamethasone (Len/Dex) is a key therapeutic option.
Framework:
- Expert panel consensus on optimal Len/Dex utilization in RRMM.
- Evidence-based recommendations for treatment initiation and duration.
- Consideration of patient-specific factors including age, disease stage, and renal function.
Implementation:
- Len/Dex is effective for most RRMM patients.
- Initiating Len/Dex at first relapse improves response rates and durability.
- Dose adjustments for lenalidomide are necessary for renal impairment and cytopenias.
Implications:
- Long-term Len/Dex therapy until disease progression is a viable strategy.
- Management of adverse events, including venous thromboembolism and myelosuppression, is crucial.
- Further research into continuous lenalidomide-based therapy is ongoing.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...